跳至主要内容
临床试验/EUCTR2021-002369-17-FR
EUCTR2021-002369-17-FR进行中(未招募)1 期

Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial.

GETAID0 个研究点目标入组 180 人开始时间: 2021年6月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
GETAID
入组人数
180

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • -Age > 18 years
  • -Diagnosis of Crohn's disease according to usual criteria
  • -Intestinal resection with ileocolonic anastomosis removing all Crohn’s disease inflammatory lesions performed within the last 6-12 months (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
  • -Postoperative endoscopy performed between 6 and 12 months +/- 2 months after ileocolonic anastomosis reaching the neoterminal ileum
  • -Postoperative endoscopic recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading
  • -The patient is willing to start infliximab CT-P13 at a fixed schedule of 2 intravenous infusions at week 0 and week 2 followed by subcutaneous CT-P13 every other week from week 6 onwards
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 180
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Patients with an ostomy
  • -Patients with ulcerative colitis or IBD type unclassified
  • -Patients with an ileorectal or ileal pouch-anal anastomosis
  • -Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions or at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
  • -Patients with symptoms of active CD, defined as average daily SF = 3.5 and average daily AP score = 1.5, having started after a free interval without symptoms of one month after surgery
  • -Patients with obstructive symptoms of CD defined by a CDOS > 4 (15) (see Appendix for description of the score). Asymptomatic patients receiving an endoscopic dilatation for a non-passable stenosis at baseline endoscopy in centres where it is a current practice to estimate the lesions extent can be included.
  • -Patients treated with any biological therapy (except for intraocular injections) or an investigational medical product after index surgery
  • -Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the faecal stream
  • -Patients in whom not all inflammatory lesions have been removed at index surgery: e.g. incomplete ileo-colonic resections, active colitis.
  • -Patients with active perianal Crohn's disease
  • -Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion, excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 3 months), recent live vaccination (within 4 weeks of baseline).
  • -Pregnant women
  • -Patients under legal protection or unable to express their consent.
  • -Patients not affiliated to a health insurance system.
  • -Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

研究者

发起方
GETAID

相似试验